Bemdaneprocel
BlueRock · Bayer
Stem cell-derived neurons
Transplanted into the brain. Motor gains held for 3 years in phase 1. Phase 3 uses sham surgery controls.
In phase 3
Neurodegenerative · movement
Parkinson's
Drugs ease symptoms but none slow the disease. The most promising front is replacing neurons with stem cells, already conditionally approved in Japan.
- Cure
- None yet
- Current treatment
- Levodopa, other symptom drugs and deep brain stimulation
- Who has it
- Over 8.5 million people worldwide
- Updated
6candidates on the board
Phase 3furthest phase
4updates in 2026
What changed
The latest developments, newest first.
ProgressFDA approves tavapadon (Juvmo)
A new kind of dopamine agonist. Added about 1 extra hour a day of good control. Treats symptoms, does not slow disease.
StoppedBIA 28-6156 fails
Pill for GBA1 carriers missed its goals.
StoppedBIIB122 fails
Biogen and Denali's LRRK2 inhibitor did not slow progression.
ProgressJapan approves a cell therapy
Raguneprocel got conditional approval based on 7 patients. Must confirm within 7 years.
Treatments in development
Each column is a step on the road to the pharmacy. Colors show the type of treatment.
- Antibody or biologic (1)
- Oral drug (2)
- Cell, gene or RNA therapy (2)
- Vaccine, device or other (1)
Phase 3confirmation · 4
Prasinezumabe
Roche
Anti-alpha-synuclein antibody
Missed its phase 2b goal but showed slowing signals. Phase 3 with ~900 people.
Result: ~2029
Solengepras
Cerevance
Non-dopamine pill
Daily add-on for motor symptoms. Phase 3 results were due Sep 2026.
Result pending
Ambroxol
Estudo ASPro-PD (Reino Unido)
Repurposed cough medicine
Boosts the GCase enzyme. Phase 3 ongoing.
In phase 3
Phase 2efficacy and dose · 2
AB-1005
AskBio · Bayer
GDNF gene therapy
Aims to protect dopamine neurons. Phase 2 with sham surgery.
Recruiting
ACI-7104
AC Immune
Alpha-synuclein vaccine
Antibodies reached spinal fluid. FDA Fast Track.
FDA talks: 2027
Left behind
Candidates that looked promising and were stopped. Most treatments tested never reach the market.
BIIB122
2026 · LRRK2 inhibitor; no effect on progression.
BIA 28-6156
2026 · GCase activator; failed phase 2b.
Exenatida
2025 · Diabetes drug; phase 3 showed no benefit.
Frequently asked questions
Is there a cure for Parkinson's?
None yet. Current treatment: Levodopa, other symptom drugs and deep brain stimulation.
Which Parkinson's treatments are being tested?
Fasevia tracks 6 candidates: Bemdaneprocel (Phase 3); Prasinezumabe (Phase 3); Solengepras (Phase 3); Ambroxol (Phase 3); AB-1005 (Phase 2); ACI-7104 (Phase 2).
What is the most advanced Parkinson's treatment in development?
The furthest along today is Bemdaneprocel (BlueRock · Bayer), in phase 3. Transplanted into the brain. Motor gains held for 3 years in phase 1. Phase 3 uses sham surgery controls.
When could a new Parkinson's treatment arrive?
A drug has to complete phase 3 and be reviewed by health agencies such as the FDA or EMA, which usually takes several years. The leading candidate today is in phase 3.